Company Filing History:
Years Active: 1976-1977
Title: Innovations by Inventor Bogdan Iliesco-Branceni
Introduction
Bogdan Iliesco-Branceni is a notable inventor based in Paris, France, recognized for his significant contributions to the field of pharmaceuticals. With a total of four patents to his name, Iliesco-Branceni has been instrumental in advancing medical treatments that address various health disorders.
Latest Patents
Bogdan Iliesco-Branceni's latest inventions include two groundbreaking patents. The first is focused on Vincaminic acid amides, which provides a novel class of compounds useful in treating pathological disturbances that involve an anoxia factor. The specific compounds described in the patent feature a structural formula where certain components can form additional bonds, enhancing their therapeutic potential.
The second patent, involving Piperazinoethyl-N-(2,3-dimethyl-5-oxo-1-phenyl-3.DELTA.-pyrazolin), presents a group of compounds that could be utilized as analgesics. The formula denotes various configurations where different hydrocarbon groups can be arranged, allowing for tailored medical applications. These compounds and their pharmaceutical salts are particularly promising for pain management.
Career Highlights
In his professional journey, Bogdan Iliesco-Branceni has made significant strides while working with Synthelabo, a leading company in the pharmaceutical industry. His innovative work not only showcases his technical skills but also reflects his commitment to improving healthcare outcomes through his inventions.
Collaborations
Throughout his career, Iliesco-Branceni has collaborated with esteemed colleagues such as Don Pierre Giudicelli and Henry Najer. These partnerships have likely fostered an environment of creativity and innovation, leading to the development of his impactful patents.
Conclusion
Bogdan Iliesco-Branceni stands out as a prominent inventor whose work continues to influence the pharmaceutical landscape. His recent patents demonstrate his dedication to addressing complex medical challenges and improving patient care. As he continues his work at Synthelabo, the future holds promising advancements for his ongoing research and innovations.